Aadi Bioscience (Nasdaq:AADI) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

AADI Overzicht aandelen

AADI fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 36.72% per jaar groeien

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( $51M )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aadi Bioscience, Inc. Concurrenten

HOOKIPA Pharma

NasdaqCM:HOOK

US$48.9m

Aligos Therapeutics

NasdaqCM:ALGS

US$53.0m

LAVA Therapeutics

NasdaqGS:LVTX

US$44.6m

Marker Therapeutics

NasdaqCM:MRKR

US$23.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Aadi Bioscience
Historische aandelenkoersen
Huidige aandelenkoers	US$1.92
52 Week Hoogtepunt	US$5.70
52 Week Laag	US$1.21
Bèta	0.37
11 maand verandering	10.34%
3 maanden verandering	44.36%
1 Jaar Verandering	-56.06%
33 jaar verandering	-92.85%
5 jaar verandering	n/a
Verandering sinds IPO	-92.62%

Recent nieuws en updates

Recent updates

Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Jul 03

Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Jul 02

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

May 10

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Mar 07

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Feb 12

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Dec 16

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Nov 10

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Oct 03

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Jun 28

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Mar 04

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

Oct 12

What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Nov 27

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

Nov 25

Rendement voor aandeelhouders

	AADI	US Biotechs	US Markt
7D	0.5%	-1.6%	-0.7%
1Y	-56.1%	17.6%	32.5%

Rendement versus industrie: AADI presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 22.1 % opleverde.

Rendement versus markt: AADI presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 34.1 % opleverde.

Prijsvolatiliteit

Is AADI's price volatile compared to industry and market?
AADI volatility
AADI Average Weekly Movement	8.4%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Stabiele aandelenkoers: AADI heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van AADI is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	70	Dave Lennon	aadibio.com

Aadi Bioscience, Inc. is een biofarmaceutisch bedrijf dat zich bezighoudt met de ontwikkeling en commercialisering van precisietherapieën voor genetisch bepaalde kankers met wijzigingen in de mTOR-routegenen. Haar belangrijkste kandidaat-geneesmiddel bestaat uit FYARRO, een vorm van sirolimus eiwitgebonden deeltjes voor injecteerbare suspensie voor de behandeling van volwassen patiënten met gevorderd onresecteerbaar of metastatisch kwaadaardig PEComa. Het bedrijf is ook betrokken bij de evaluatie van FYARRO bij kanker, waaronder indicaties gericht op specifieke genoomveranderingen die de mTOR-route activeren.

Aadi Bioscience, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Aadi Bioscience zich tot de beurswaarde?
AADI fundamentele statistieken
Marktkapitalisatie	US$48.25m
Inkomsten(TTM)	-US$65.44m
Inkomsten(TTM)	US$23.82m

2.0x

P/S-verhouding

-0.7x

Koers/Winstverhouding

Is AADI overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AADI resultatenrekening (TTM)
Inkomsten	US$23.82m
Kosten van inkomsten	US$54.40m
Brutowinst	-US$30.58m
Overige uitgaven	US$34.86m
Inkomsten	-US$65.44m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.66
Brutomarge	-128.40%
Nettowinstmarge	-274.77%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde AADI op de lange termijn?

Bekijk historische prestaties en vergelijking

AADI Overzicht aandelen

Beloningen

Risicoanalyse

Aadi Bioscience, Inc. Concurrenten

NasdaqCM:HOOK

US$48.9m

NasdaqCM:ALGS

US$53.0m

NasdaqGS:LVTX

US$44.6m

NasdaqCM:MRKR

US$23.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Aadi Bioscience, Inc. Approves Plan of Termination That Will Result in Workforce Reduction of 22 Employees, Representing Approximately 32% of the Workforce

Aadi Bioscience Provides PRECISION1 Trial Updates

Consensus estimates of losses per share improve by 12%

Price target decreased by 14% to US$10.00

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Aadi Bioscience, Inc. Approves Plan of Termination That Will Result in Workforce Reduction of 22 Employees, Representing Approximately 32% of the Workforce

Aadi Bioscience Provides PRECISION1 Trial Updates

Consensus estimates of losses per share improve by 12%

Price target decreased by 14% to US$10.00

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Comp Value Index

Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Founder & Executive Chairman notifies of intention to sell stock

Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

Consensus revenue estimates decrease by 14%, EPS upgraded

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

New minor risk - Profitability

Forecast to breakeven in 2026

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$2.44 loss per share (vs US$2.69 loss in FY 2022)

Aadi Bioscience, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Founder notifies of intention to sell stock

Aadi Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Price target decreased by 67% to US$11.67

Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Founder notifies of intention to sell stock

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

New minor risk - Share price stability

Aadi Bioscience, Inc. Announces Chief Executive Officer Changes

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Founder notifies of intention to sell stock

Consensus EPS estimates fall by 10%

Second quarter 2023 earnings: EPS misses analyst expectations

Aadi Bioscience, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Founder notifies of intention to sell stock

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Consensus revenue estimates increase by 11%, EPS downgraded

Price target decreased by 8.8% to US$38.75

First quarter 2023 earnings released: US$0.57 loss per share (vs US$0.66 loss in 1Q 2022)

Founder notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience, Inc. Announces Management Changes

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience, Inc. Announces Executive Changes, Effective January 1, 2023

Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Aadi Bioscience: Taking mTOR Inhibition To The Next Level

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aadi Bioscience, Inc. Reports Impairment of Intangible Asset for the Second Quarter Ended June 30, 2022

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Microcap Value Index

Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes